Most Read Articles
26 Aug 2017
Elderly individuals with high levels of serum uric acid may be at an increased risk of dementia, particularly vascular or mixed dementia, a study suggests.
14 Jan 2016
Tocotrienols are one of the two classes of compounds generally known as vitamin E. Prominent researcher in pharmaceutical technology, Professor Yuen Kah Hay, recently spoke to MIMS Doctor about the neuroprotective benefits conferred by palm tocotrienols. He shared key insights from a clinical trial performed by his team and about the compound’s potential for clinical use.
Elvira Manzano, 01 Feb 2014

There is no benefit to using ibuprofen over paracetamol in most patients with upper respiratory tract infections (URTIs). Steam inhalation therapy also does not offer any advantage, research has shown.

Dr. Joseph Delano Fule Robles, 01 Mar 2017

The tau and Aβ amyloid pathways have emerged as possible novel targets in treating Alzheimer’s disease (AD), according to studies discussed at the recently concluded Hong Kong Pharmacy Conference.

Moderate-to-severe traumatic brain injury ups risk of dementia

30 Jul 2017
By integrating current dementia aids with advances in robotic technology and digital communications, dementia patients can have a better quality of life.

The risk of future dementia is higher for working-aged individuals with histories of moderate-to-severe traumatic brain injuries (TBI), a new retrospective cohort study has found. The risk of Parkinson’s disease (PD) or amyotrophic lateral sclerosis (ALS) is unaffected.

The study included 19,936 working-aged, moderate-to-severe TBI patients (mean age 46 years; 23 percent female). Working-aged individuals hospitalized for mild TBIs (n=20,703; mean age 39 years; 39 percent female) were included as controls. The study outcome was the development of neurodegenerative disorders (NDD) including dementia, PD or ALS.

Over the course of the study, 3.5 percent (n=696) of participants with moderate-to-severe TBI developed NDD. In comparison, only 1.6 percent (n=326) of the mild TBI patients had NDD, with the between-group difference reaching significance (p<0.001).

Dementia was the most common NDD type and was observed in 3.1 and 1.3 percent of the moderate-to-severe and mild TBI groups, respectively. This was followed by PD (0.3 and 0.2 percent, respectively) and ALS (0.1 and 0.1 percent, respectively).

The unadjusted NDD rate for the moderate-to-severe and mild TBI groups were 331 and 134 per 100,000 person-years, respectively. Unadjusted rates for dementia (293 vs 114 per 100,000 person-ears), PD (32 vs 17 per 100,000 person-years) and ALS (6 vs 4 per 100,000 person-years) were all higher in the moderate-to-severe TBI group.

The risk of NDD was significantly higher in the moderate-to-severe TBI group compared with the mild TBI group after adjusting for age, sex, level of education and socioeconomic group (hazard ratio [HR], 1.8; 95 percent CI, 1.6 to 2.1; p<0.001).

Adjusted models also showed a higher risk of dementia (HR, 1.9; 1.6 to 2.2; p<0.001) but not PD (HR, 1.3; 0.9 to 1.9; p=0.22) and ALS (HR, 1.3; 0.5 to 3.2; p=0.53) in moderate-to-severe TBI patients. 
Editor's Recommendations
Most Read Articles
26 Aug 2017
Elderly individuals with high levels of serum uric acid may be at an increased risk of dementia, particularly vascular or mixed dementia, a study suggests.
14 Jan 2016
Tocotrienols are one of the two classes of compounds generally known as vitamin E. Prominent researcher in pharmaceutical technology, Professor Yuen Kah Hay, recently spoke to MIMS Doctor about the neuroprotective benefits conferred by palm tocotrienols. He shared key insights from a clinical trial performed by his team and about the compound’s potential for clinical use.
Elvira Manzano, 01 Feb 2014

There is no benefit to using ibuprofen over paracetamol in most patients with upper respiratory tract infections (URTIs). Steam inhalation therapy also does not offer any advantage, research has shown.

Dr. Joseph Delano Fule Robles, 01 Mar 2017

The tau and Aβ amyloid pathways have emerged as possible novel targets in treating Alzheimer’s disease (AD), according to studies discussed at the recently concluded Hong Kong Pharmacy Conference.